Uterine Fibroids or Endometriosis - Columbus OH

Summary:

Follow changes in bone mineral density (BMD) over time when Myfembree® (relugolix combination tablet) is used for up to 4 years. Currently, this medicine is approved by the United States (US) Food and Drug Administration (FDA) for up to 2 years of use for the management of premenopausal women with heavy menstrual bleeding associated with uterine fibroids or moderate to severe pain associated with endometriosis.

Visits are every 6 months at the clinic for 5 years.

1.           Premenopausal woman, 18 to 50 years of age.

2.           Has a diagnoses of either uterine fibroids or endometriosis

3.           Has a body mass index (BMI) ≥ 18 kg/m2

4.           Is willing to avoid pregnancy for 4 years using non-hormonal methods of contraception

5.           No history of low trauma fracture

Qualified Participants May Receive:

Up to $3,513.00 for study completion.